Efficacy and Safety of Natural Apigenin Treatment for Alzheimer's Disease: Focus on In vivo Research Advancements.

IF 4.8 2区医学 Q1 NEUROSCIENCES

Current Neuropharmacology Pub Date : 2025-01-01 DOI:10.2174/1570159X23666241211095018

Nan Zhang, Jianfei Nao, Xiaoyu Dong

{"title":"Efficacy and Safety of Natural Apigenin Treatment for Alzheimer's Disease: Focus on In vivo Research Advancements.","authors":"Nan Zhang, Jianfei Nao, Xiaoyu Dong","doi":"10.2174/1570159X23666241211095018","DOIUrl":null,"url":null,"abstract":"Background: Alzheimer's Disease (AD) is the most common dementia in clinics. Despite decades of progress in the study of the pathogenesis of AD, clinical treatment strategies for AD remain lacking. Apigenin, a natural flavonoid compound, is present in a variety of food and Chinese herbs and has been proposed to have a wide range of therapeutic effects on dementia.Objective: To clarify the relevant pharmacological mechanism and therapeutic effect of apigenin on animal models of AD.Methods: Computer-based searches of the PubMed, Cochrane Library, Embase, and Web of Science databases were used to identify preclinical literature on the use of apigenin for treating AD. All databases were searched from their respective inception dates until June 2023. The meta-analysis was performed with Review manager 5.4.1 and STATA 17.0.Results: Thirteen studies were eventually enrolled, which included 736 animals in total. Meta-analysis showed that apigenin had a positive effect on AD. Compared to controls, apigenin treatment reduced escape latency, increased the percentage of time spent in the target quadrant and the number of plateaus traversed; apigenin was effective in reducing nuclear factor kappa-B (NF-κB) p65 levels; apigenin effectively increased antioxidant molecules SOD and GSH-px and decreased oxidative index MDA; for ERK/CREB/BDNF pathway, apigenin effectively increased BDNF and pCREB molecules; additionally, apigenin effectively decreased caspase3 levels and the number of apoptotic cells in the hippocampus.Conclusion: The results show some efficacy of apigenin in the treatment of AD models. However, further clinical studies are needed to confirm the clinical efficacy of apigenin.","PeriodicalId":10905,"journal":{"name":"Current Neuropharmacology","volume":" ","pages":"728-754"},"PeriodicalIF":4.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Neuropharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1570159X23666241211095018","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Alzheimer's Disease (AD) is the most common dementia in clinics. Despite decades of progress in the study of the pathogenesis of AD, clinical treatment strategies for AD remain lacking. Apigenin, a natural flavonoid compound, is present in a variety of food and Chinese herbs and has been proposed to have a wide range of therapeutic effects on dementia.

Objective: To clarify the relevant pharmacological mechanism and therapeutic effect of apigenin on animal models of AD.

Methods: Computer-based searches of the PubMed, Cochrane Library, Embase, and Web of Science databases were used to identify preclinical literature on the use of apigenin for treating AD. All databases were searched from their respective inception dates until June 2023. The meta-analysis was performed with Review manager 5.4.1 and STATA 17.0.

Results: Thirteen studies were eventually enrolled, which included 736 animals in total. Meta-analysis showed that apigenin had a positive effect on AD. Compared to controls, apigenin treatment reduced escape latency, increased the percentage of time spent in the target quadrant and the number of plateaus traversed; apigenin was effective in reducing nuclear factor kappa-B (NF-κB) p65 levels; apigenin effectively increased antioxidant molecules SOD and GSH-px and decreased oxidative index MDA; for ERK/CREB/BDNF pathway, apigenin effectively increased BDNF and pCREB molecules; additionally, apigenin effectively decreased caspase3 levels and the number of apoptotic cells in the hippocampus.

Conclusion: The results show some efficacy of apigenin in the treatment of AD models. However, further clinical studies are needed to confirm the clinical efficacy of apigenin.

查看原文本刊更多论文

天然芹菜素治疗阿尔茨海默病的有效性和安全性：体内研究进展

背景：阿尔茨海默病（AD）是临床上最常见的痴呆症。尽管几十年来对阿尔茨海默病发病机制的研究取得了进展，但阿尔茨海默病的临床治疗策略仍然缺乏。芹菜素是一种天然的类黄酮化合物，存在于各种食物和中草药中，并被认为对痴呆症有广泛的治疗作用。目的：阐明芹菜素对AD动物模型的相关药理机制及治疗作用。方法：基于计算机检索PubMed、Cochrane图书馆、Embase和Web of Science数据库，确定使用芹菜素治疗AD的临床前文献。所有数据库从各自的建立日期开始搜索，直到2023年6月。meta分析采用Review manager 5.4.1和STATA 17.0进行。结果：最终纳入13项研究，共纳入736只动物。meta分析显示，芹菜素对AD有积极作用。与对照组相比，芹菜素治疗减少了逃避潜伏期，增加了在目标象限花费的时间百分比和穿越高原的次数；芹菜素能显著降低核因子κ b (NF-κB) p65水平；芹菜素有效提高抗氧化分子SOD和GSH-px，降低氧化指数MDA；对于ERK/CREB/BDNF通路，芹菜素有效增加BDNF和pCREB分子；此外，芹菜素可有效降低海马中caspase3水平和凋亡细胞数量。结论：芹菜素对AD模型有一定的治疗作用。然而，芹菜素的临床疗效还需要进一步的临床研究来证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Neuropharmacology 医学-神经科学

CiteScore

8.70

自引率

1.90%

发文量

369

审稿时长

>12 weeks

期刊介绍： Current Neuropharmacology aims to provide current, comprehensive/mini reviews and guest edited issues of all areas of neuropharmacology and related matters of neuroscience. The reviews cover the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience. The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.